Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.

IFN-free regimens with direct antiviral agents (DAAs) against hepatitis C virus (HCV) are likely to greatly expand patients' access and response to hepatitis C therapy, while safety and tolerability of treatments seem substantially improved. Sofosbuvir (SOF), a NS5B nucleotide polymerase inhibitor with pan-genotypic activity and a high-barrier to resistance, has been approved by FDA and EMA in an all oral combination therapy for chronic hepatitis C with ribavirin (RBV) alone, or in combination with either pegylated interferon/RBV or other DAAs.
This paper provides an overview of SOF-based therapy in chronic hepatitis C as it emerges from the published clinical trials. Data on special populations are included (i.e., decompensated patients, patients on liver transplant waiting lists, patients with renal impairment). The data has been analyzed according to the different HCV-genotypes and comprehensively covers both safety and efficacy treatment profiles.
Clinical trials have highlighted the safety and efficacy of SOF-based regimens, leading to the rapid approval of this therapy and its incorporation in the recommendations of the international societies on treatment of HCV infection. However, additional data are still needed to optimize both combination therapies' efficacy and duration in some categories of patients who have been under-represented in the registration trials.
AuthorsRoberta D'Ambrosio, Alessio Aghemo, Massimo Colombo
JournalExpert opinion on drug safety (Expert Opin Drug Saf) Vol. 14 Issue 3 Pg. 473-84 (Mar 2015) ISSN: 1744-764X [Electronic] England
PMID25645644 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antiviral Agents
  • Uridine Monophosphate
  • Sofosbuvir
  • Antiviral Agents (administration & dosage, adverse effects, therapeutic use)
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • Genotype
  • Hepacivirus (genetics, isolation & purification)
  • Hepatitis C, Chronic (drug therapy, virology)
  • Humans
  • Sofosbuvir
  • Treatment Outcome
  • Uridine Monophosphate (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: